Skip to content
Company Analysis

Bausch Health Companies Inc. BHC

A comprehensive view of key metrics, scores, and financial health for Bausch Health Companies Inc.

Overview of Bausch Health Companies Inc.

BHC NYQ
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Mid Cap
Bausch Health Companies Inc. (BHC), is a Mid Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $8.02, about 655.6% undervalued vs fair value, +19.9% 1Y return, ranked 710/1145 in sector.
Metrics P/E 16.5× Rev Growth 6.7% ROE -17.1% Gross Margin 70.7%
USD 8.02
-2.20%
(Delayed)
• Vol 90d: 80.0%
52-Week Range
Market Cap
$3.00B
Enterprise Value
$22.89B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 100%
Confidence: 96%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.bauschhealth.com
HQ Laval, QC
Employees 20,300
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$55
$61
$66
Current: $8.02 +656% vs base

Engine Room Money Flow™

Mid Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$10.3B
6.7%%
Gross Profit
$7.3B
6%%
R&D Expense
$629.0M
2.1%%
Operating Income (EBIT)
$2.0B
26.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
71.0%
Fair

Moderate cash conversion - some working capital drag

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
5
Active Leaks
3/5
Improving
1
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Bausch Health Companies Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
68
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.89), demonstrating pricing resilience across cycles.
  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.99), suggesting sticky customer base.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.37), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.28), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
83
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 87% Coverage
Trade-Off Triangle Visualization A ternary plot showing BHC's balance between Growth (37.4%), Profitability (40.8%), and Safety (21.8%). Growth 37% Safety 22% Profitability 41%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

62th percentile vs peers
62
Key Signals
EPS Growth YoY 4.23 91p Rev Growth YoY 6.7% 60p Revenue CAGR 3Y 8.1% 62p TSR -76.9% 6p
Strengths
  • EPS Growth YoY in top 20% of peers (4.23, 91th percentile)
  • Superior capital returns - 2 return metrics above peer median
  • Growth above peer median with strong metric coverage (85%)
  • Consistently strong margins across 6 metrics
Risks

No significant risks identified for this axis.

Profitability

67th percentile vs peers
68
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

36th percentile vs peers
36
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Bausch Health Companies Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$60.60
- - -
+655.6% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000